Azacitidine, long used against high-risk myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), appears to kill leukaemia cells in the first day of treatment mainly by acting on RNA rather than DNA. A study in Molecular Cell by researchers at the University of Chicago and UT Health San Antonio identifies…
SL
